JITC Increases Impact Factor to 8.676The Journal for ImmunoTherapy of Cancer (JITC), SITC’s open access, peer-reviewed online journal, has increased its impact factor to 8.676.
June is Cancer Immunotherapy Awareness Month™
SITC Cancer Immunotherapy Guidelines: Consensus statements that help oncologists determine when and how to best use immunotherapy to treat cancer patients in a variety of disease states.
SITC 2019 General Registration Now Open!New session, presentation and speaker information now available!
New in JITC: Cancer Immune Responsiveness Workshop ManuscriptToward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
REGISTER TODAYJoin SITC for two back-to-back immuno-oncology workshops.Sept. 4 - 6, 2019 | Houston, Texas
NOW AVAILABLE: SITC's Guide to Managing Immunotherapy Toxicity A new handbook from SITC for clinicians providing thorough coverage of the toxicity and management of adverse events for immune checkpoint inhibitors.
Winter School Enduring Materials Now Available to Public
Presentations from the 2019 Cancer Immunotherapy Winter School hosted Feb. 18–22, 2019, are now available to the general public.
Submit an abstract for SITC 2019 Submit a regular abstract, Young Investigator Award abstract and/or late-breaking abstract application by 5 p.m. PDT on Aug. 1, 2019.
Join Patrick Hwu, MD, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
Inspire the Next Generation of Cancer Immunotherapy Leaders
Advance the science of cancer immunotherapy and help young investigators tackle hurdles facing the field with a gift to the SITC Forward Fund.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Thank you Fabiana! Suggestions noted. For starters, if you have not yet done that, please apply to the WIN database (Women in Cancer Immunotherapy network) under the volunteer options. WIN is looking to create a database that can be used to better identify ...
Hi Priscilla, it is a fact that women face additional challenges at advancing their careers compared to their male peers. I suggest we create more spots to increase female colleagues visibility at conferences (chairing sessions for instance) and perhaps ...
Hello ladies I am excited to share that I am now a member of the SITC Early Career Scientist Committee! I would love to hear from you regarding any ideas/suggestions on how this committee can help women improve their careers in immunology. Priscila ------------------------------ ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com